Targeted Therapeutics Market Size To Reach USD 144.62 Billion By 2032 Report By DataHorizzon Research
23. Januar 2024 06:40 ET
|
DataHorizzon Research
Fort Collins, Colorado, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The Targeted Therapeutics Market size was valued at USD 74.21 Billion in 2022 and is anticipated to reach USD 144.62 Billion by 2032 at a...
Global Targeted Therapeutics Market Size to Reach USD 214.31 Billion in 2032 | Emergen Research
16. Oktober 2023 09:09 ET
|
Emergen Research
Vancouver, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Current Market Scenario (Market estimates) The global Targeted Therapeutics Market size was USD 93.75 Billion in 2020. Increasing prevalence of cancer,...
Targeted Therapeutics Market Size & Share to Surpass $80.9 Billion by 2030 | Vantage Market Research
19. September 2023 09:13 ET
|
Vantage Market Research
WASHINGTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Targeted Therapeutics Market has been steadily growing over the years due to the increasing prevalence of...
bioAffinity Awarded New Patent; Company’s Patent Portfolio Continues to Expand
24. August 2016 09:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Texas, Aug. 24, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies today announced that it has been awarded a U.S. Patent protecting a proprietary kit that contains the...
bioAffinity Technologies and UT Health Science Center Collaborate to Optimize Cancer Diagnostics and Therapeutics
13. Juli 2016 08:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, July 13, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies today announced the renewal of its collaborative agreement with The University of Texas Health Science Center at San Antonio...
bioAffinity Technologies Appoints New Senior VP for Research & Development of Therapeutics
07. Juli 2016 08:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, July 07, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies today announced that William Bauta, Ph.D., will join the company in September 2016 as Senior Vice President for Research and...
bioAffinity Technologies Forms Subsidiary to Focus on Targeted Cancer Drug Delivery
23. Juni 2016 08:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Texas, June 23, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies today announced the formation of OncoSelect Therapeutics, LLC, a subsidiary company that will leverage bioAffinity’s...